Mildronate, an Inhibitor of Carnitine Biosynthesis, Induces an Increase in Gamma-Butyrobetaine Contents and Cardioprotection in Isolated Rat Heart Infarction
- 1 December 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 48 (6) , 314-319
Abstract
The inhibition of gamma-butyrobetaine (GBB) hydroxylase, a key enzyme in the biosynthesis of carnitine, contributes to lay ground for the cardioprotective mechanism of action of mildronate. By inhibiting the biosynthesis of carnitine, mildronate is supposed to induce the accumulation of GBB, a substrate of GBB hydroxylase. This study describes the changes in content of carnitine and GBB in rat plasma and heart tissues during long-term (28 days) treatment of mildronate [i.p. (intraperitoneal) 100 mg/kg/daily]. Obtained data show that in concert with a decrease in carnitine concentration, the administration of mildronate caused a significant increase in GBB concentration. We detected about a 5-fold increase in GBB contents in the plasma and brain and a 7-fold increase in the heart. In addition, we tested the cardioprotective effect of mildronate in isolated rat heart infarction model after 3, 7, and 14 days of administration. We found a statistically significant decrease in necrotic area of infarcted rat hearts after 14 days of treatment with mildronate. The cardioprotective effect of mildronate correlated with an increase in GBB contents. In conclusion, our study, for the first time, provides experimental evidence that the long-term administration of mildronate not only decreases free carnitine concentration, but also causes a significant increase in GBB concentration, which correlates with the cardioprotection of mildronate.Keywords
This publication has 18 references indexed in Scilit:
- l-Carnitine is Synthesized in the Human Fetal–Placental Unit: Potential Roles in Placental and Fetal MetabolismPlacenta, 2006
- Carnitine biosynthesis in mammalsBiochemical Journal, 2002
- Effects of MET-88, a .GAMMA.-Butyrobetaine Hydroxylase Inhibitor, on Tissue Carnitine and Lipid Levels in Rats.Biological and Pharmaceutical Bulletin, 2000
- CARNITINE METABOLISM AND ITS REGULATION IN MICROORGANISMS AND MAMMALSAnnual Review of Nutrition, 1998
- Cardioprotective profile of MET‐88, an inhibitor of carnitine synthesis, and insulin during hypoxia in isolated perfused rat heartsFundamental & Clinical Pharmacology, 1998
- Effect of MET‐88, a γ‐butyrobetaine hydroxylase inhibitor, on myocardial derangements induced by hydrogen peroxide in the isolated perfused rat heartFundamental & Clinical Pharmacology, 1997
- Determination of l-carnitine, acetyl-l-carnitine and propionyl-l-carnitine in human plasma by high-performance liquid chromatography after pre-column derivatization with 1-aminoanthraceneJournal of Chromatography B: Biomedical Sciences and Applications, 1996
- CARNITINEAnnual Review of Biochemistry, 1988
- 3-(2,2,2-Trimethylhydrazinium)propionate(thp)-a novel γ-butyrobetaine hydroxylase inhibitor with cardioprotective propertiesBiochemical Pharmacology, 1988
- Carnitine--metabolism and functionsPhysiological Reviews, 1983